Your browser doesn't support javascript.
loading
In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery.
Cano Garcia, Cristina; Tappero, Stefano; Piccinelli, Mattia Luca; Barletta, Francesco; Incesu, Reha-Baris; Morra, Simone; Scheipner, Lukas; Baudo, Andrea; Tian, Zhe; Hoeh, Benedikt; Chierigo, Francesco; Sorce, Gabriele; Saad, Fred; Shariat, Shahrokh F; Carmignani, Luca; Ahyai, Sascha; Longo, Nicola; Tilki, Derya; Briganti, Alberto; De Cobell, Ottavio; Dell'Oglio, Paolo; Mandel, Philipp; Terrone, Carlo; Chun, Felix K H; Karakiewicz, Pierre I.
Afiliação
  • Cano Garcia C; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada. cristina.canogarcia@kgu.de.
  • Tappero S; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany. cristina.canogarcia@kgu.de.
  • Piccinelli ML; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
  • Barletta F; Department of Urology, Ospedale Policlinico San Martino, Genoa, Italy.
  • Incesu RB; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genoa, Italy.
  • Morra S; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
  • Scheipner L; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Baudo A; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
  • Tian Z; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Hoeh B; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
  • Chierigo F; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Sorce G; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
  • Saad F; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples Federico II, Naples, Italy.
  • Shariat SF; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
  • Carmignani L; Department of Urology, Medical University of Graz, Graz, Austria.
  • Ahyai S; Department of Urology, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy.
  • Longo N; Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.
  • Tilki D; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
  • Briganti A; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • De Cobell O; Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Dell'Oglio P; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Mandel P; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montreal, QC, Canada.
  • Terrone C; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Chun FKH; Department of Urology, Weill Cornell Medical College, New York, NY, USA.
  • Karakiewicz PI; Department of Urology, University of Texas Southwestern, Dallas, TX, USA.
Ann Surg Oncol ; 30(13): 8770-8779, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37721691
BACKGROUND: This study aimed to test for temporal trends of in-hospital venous thromboembolism (VTE) and pulmonary embolism (PE) after major urologic cancer surgery (MUCS). METHODS: In the Nationwide Inpatient Sample (NIS) database (2010-2019), this study identified non-metastatic radical cystectomy (RC), radical prostatectomy (RP), radical nephrectomy (RN), and partial nephrectomy (PN) patients. Temporal trends of VTE and PE and multivariable logistic regression analyses (MLR) addressing VTE or PE, and mortality with VTE or PE were performed. RESULTS: Of 196,915 patients, 1180 (1.0%) exhibited VTE and 583 (0.3%) exhibited PE. The VTE rates increased from 0.6 to 0.7% (estimated annual percentage change [EAPC] + 4.0%; p = 0.01). Conversely, the PE rates decreased from 0.4 to 0.2% (EAPC - 4.5%; p = 0.01). No difference was observed in mortality with VTE (EAPC - 2.1%; p = 0.7) or with PE (EAPC - 1.2%; p = 0.8). In MLR relative to RP, RC (odds ratio [OR] 5.1), RN (OR 4.5), and PN (OR 3.6) were associated with higher VTE risk (all p < 0.001). Similarly in MLR relative to RP, RC (OR 4.6), RN (OR 3.3), and PN (OR 3.9) were associated with higher PE risk (all p < 0.001). In MLR, the risk of mortality was higher when VTE or PE was present in RC (VTE: OR 3.7, PE: OR  4.8; both p < 0.001) and RN (VTE: OR 5.2, PE: OR  8.3; both p < 0.001). CONCLUSIONS: RC, RN, and PN predisposes to a higher VTE and PE rates than RP. Moreover, among RC and RN patients with either VTE or PE, mortality is substantially higher than among their VTE or PE-free counterparts.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Neoplasias Urológicas / Tromboembolia Venosa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Neoplasias Urológicas / Tromboembolia Venosa Idioma: En Ano de publicação: 2023 Tipo de documento: Article